Line Hammer Dohn

Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial

Christina H. Ruhlmann, Line Hammer Dohn, Merete Paludan et al. · The Lancet Oncology · 2016 · 47 citations

Medicine, Oncology, Pharmacology +13

Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy – a feasibility study

Gry Assam Taarnhøj, Henriette Lindberg, Line Hammer Dohn et al. · Health and Quality of Life Outcomes · 2020 · 41 citations · Full text

Medicine, Health Informatics, Oncology +13

Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder

Line Hammer Dohn, Martin Illemann, Gunilla Høyer‐Hansen et al. · Urologic Oncology Seminars and Original Investigations · 2015 · 29 citations

Medicine, Oncology, Urology +10

1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial

Jørgen Bjerggaard Jensen, Karin Birkenkamp‐Demtröder, Iver Nordentoft et al. · Annals of Oncology · 2024 · 28 citations · Full text

Medicine, Oncology, Urology +12

uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder – Possible Clinical Implications

Line Hammer Dohn, Helle Pappot, Benedikte Richter Iversen et al. · PLoS ONE · 2015 · 18 citations · Full text

Medicine, Oncology, Urology +16